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A Saccharomyces cerevisiae Model Reveals
In Vivo Functional Impairment of the Ogden
Syndrome N-Terminal Acetyltransferase NAA10
Ser37Pro Mutant*□S
Petra Van Damme‡§‡‡, Svein I. Støve¶**, Nina Glomnes¶, Kris Gevaert‡§,
and Thomas Arnesen¶**‡‡
N-terminal acetylation (Nt-acetylation) occurs on the ma-
jority of eukaryotic proteins and is catalyzed by N-termi-
nal acetyltransferases (NATs). Nt-acetylation is increas-
ingly recognized as a vital modification with functional
implications ranging from protein degradation to protein
localization. Although early genetic studies in yeast dem-
onstrated that NAT-deletion strains displayed a variety of
phenotypes, only recently, the first human genetic disor-
der caused by a mutation in a NAT gene was reported;
boys diagnosed with the X-linked Ogden syndrome har-
bor a p.Ser37Pro (S37P) mutation in the gene encoding
Naa10, the catalytic subunit of the NatA complex, and
suffer from global developmental delays and lethality dur-
ing infancy. Here, we describe a Saccharomyces cerevi-
siaemodel developed by introducing the human wild-type
or mutant NatA complex into yeast lacking NatA (NatA-).
The wild-type human NatA complex phenotypically com-
plemented the NatA- strain, whereas only a partial res-
cue was observed for the Ogden mutant NatA complex
suggesting that hNaa10 S37P is only partially functional in
vivo. Immunoprecipitation experiments revealed a reduced
subunit complexation for the mutant hNatA S37P next to a
reduced in vitro catalytic activity. We performed quantita-
tive Nt-acetylome analyses on a control yeast strain
(yNatA), a yeast NatA deletion strain (yNatA-), a yeast NatA
deletion strain expressing wild-type human NatA (hNatA),
and a yeast NatA deletion strain expressing mutant human
NatA (hNatA S37P). Interestingly, a generally reduced de-
gree of Nt-acetylation was observed among a large group
of NatA substrates in the yeast expressing mutant hNatA as
compared with yeast expressing wild-type hNatA. Com-
bined, these data provide strong support for the functional
impairment of hNaa10 S37P in vivo and suggest that re-
duced Nt-acetylation of one or more target substrates con-
tributes to the pathogenesis of the Ogden syndrome. Com-
parative analysis between human and yeast NatA also
provided new insights into the co-evolution of the NatA
complexes and their substrates. For instance, (Met-)Ala-
N termini are more prevalent in the human proteome as
compared with the yeast proteome, and hNatA displays
a preference toward these N termini as compared with
yNatA. Molecular & Cellular Proteomics 13: 10.1074/
mcp.M113.035402, 2031–2041, 2014.
Up to 85% of soluble eukaryotic proteins carry an N-termi-
nal acetyl group at their N terminus, which is the result of a
co-translational protein modification referred to as N-terminal
protein acetylation (Nt-acetylation) or N-acetylation (1). This
presumed irreversible protein modification is catalyzed by a
specific category of the GCN5-related N-acetyltransferase
domain containing superfamily of acetyltransferases; the ri-
bosome associated N-terminal acetyltransferases or NATs1
(2). NATs catalyze the acetyl transfer from acetyl coenzyme A
(Ac-CoA) to a primary -amine of the first amino acid residue
of a nascent protein chain. In eukaryotes, NATs are com-
posed of at least one catalytic subunit and mainly target
different substrate N termini based on their N-terminal se-
quences (3).
To date, five human NATs hNatA, hNatB, and hNatC; con-
stituting the major human NAT complexes, and hNatD and
hNatF have been identified and their substrate specificity
characterized (1, 4–8). In addition, a putative hNatE complex
has been described (9–10). Except for NatF, which is only
expressed in higher eukaryotes (1), the substrate specificity
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profiles of the NatA-E complexes seem to be conserved
among eukaryotes (5–9, 11–13).
Contrary to the original assumption that Nt-acetylation pro-
tected proteins from degradation (14), it was more recently
demonstrated that this modification creates specific degra-
dation signals (termed Ac/N-degrons) in cellular proteins,
thereby diversifying this original view substantially. These de-
grons target at least some Nt-acetylated proteins for the
conditional degradation by a novel branch of the N-end rule
pathway, an ubiquitin-dependent proteolytic system (15–16).
In addition, numerous reports implicate Nt-acetylation in cel-
lular differentiation, survival, metabolism, and proliferation,
thereby linking it to cancer (17–18). As such, Nt-acetylation is
now linked to a whole range of molecular implications includ-
ing protein destabilization and degradation by the Nt-acety-
lation dependent recruitment of ubiquitin ligases (15–16),
protein translocation (19), membrane attachment (20), and
protein complex formation (21).
Among all characterized NATs, NatA displays the broadest
substrate specificity profile and thus represents the primary
NAT in terms of substrate N termini as it is responsible for the
Nt-acetylation of the methionine aminopeptidase (MetAP)
iMet-processed serine, threonine, alanine, glycine, and valine
starting N termini (3). The human NatA complex is composed
of two essential subunits; the catalytic subunit hNaa10
(hARD1) and the regulatory subunit hNaa15 (NATH/hNAT1)
(4). Deregulations of hNaa10 and/or NatA expression have
been linked to various signaling molecules including hypoxia
inducible factor-1, DNA methyltransferase1/E-cadherin,
-catenin/cyclin D1, and Bcl-xL, showing its involvement in
hypoxia, tumorigenesis, cell cycle progression, and apoptosis
(17, 22–26).
Recently, the first structures of NATs and a NAT-complex
were solved, providing a molecular understanding of the se-
quence specific Nt-acetylation of protein N termini (27–30).
Structural analyses of noncomplexed Naa10 and NatA from
Schizosaccharomyces pombe reveal an allosteric modulator
function of Naa15 in steering Naa10 specificity and provide a
rational for the distinctive substrate specificity profiles ob-
served when assaying non-complexed versus complexed
Naa10 (10, 27), with both forms co-existing in cells (10). In
particular, three essential catalytic Naa10 residues were
found to be incorrectly positioned in non-complexed Naa10,
while these shift into the active site in Naa15-complexed
Naa10, thereby permitting canonical NatA-mediated Nt-
acetylation. Interestingly, noncomplexed Naa10 was shown to
efficiently Nt-acetylate glutamate and aspartate starting N
termini, whereas poorly acetylating canonical NatA type N
termini (10). The study of Liszczak et al. further showed that
NatA substrate binding specificity was coupled to the cata-
lytic mechanism being used (27). More specifically, an essen-
tial glutamate residue (Glu24 in the protein accession Q9UTI3
(Swiss-Prot)) involved in catalysis, precludes methionine from
entering the specificity pocket, whereas cognate NatA sub-
strate N-terminal residues can easily be accommodated. In-
terestingly, and in contrast to NatA, both wild-type Naa10 and
Glu24 mutated Naa10 (Naa10 E24A) were still capable of
Nt-acetylating acidic amino acid starting N termini, most likely
because of the substrate side-chain carboxyl moiety acting as
a functional replacement group in the process of catalysis,
whereas essentially no activity could be observed when prob-
ing a cognate NatA substrate (27).
Early yeast studies demonstrated that strains with mutated
or deleted NAT genes were viable, but displayed a number of
different phenotypes (31). For NatA, the first phenotypes de-
scribed were defects in sporulation, mating, and entry into
stationary phase when NAA10 (ARD1) was mutated (32). Four
years later, the overlapping phenotypes of NAA10 and NAA15
(NAT1) mutant strains, revealed, along with other data, that
Naa10 and Naa15 are in fact components of the NatA acetyl-
transferase complex (33–34). As compared with NatA pheno-
types, NatB phenotypes are more severe, including slow
growth and defects in mitochondrial inheritance (35–36). NatC
subunits were initially found to be essential for propagation of
the L-A dsRNA virus, and further for growth on nonferment-
able carbon sources (37–39). The first reports implicating NAT
gene point mutations in human genetic disorders only recently
emerged. More specifically, two different point mutations in
the X-linked NAA10 gene were both found to cause develop-
mental delays and were linked to the Ogden syndrome (S37P)
(40) and intellectual disability (R116W) (41), highlighting the
essential importance of NATs and protein Nt-acetylation in
biology and disease. Further, in Caenorhabditis elegans (42),
Drosophila melanogaster (43), and Trypanosoma brucei (44),
Naa10 was proven to be essential and, strengthened by the
observed detrimental effects of NAA10 mutations (40–41),
the NAA10 gene function is also believed to be essential in
human.
Ogden syndrome boys harboring the p.Ser37Pro variant in
the gene encoding Naa10 are characterized by craniofacial
abnormalities, failure to thrive, developmental delay, hypoto-
nia, cardiac arrhythmias, cryptorchidism, and an aged ap-
pearance, ultimately resulting in mortality during infancy (40).
Although this mutation was shown to significantly impair
Naa10 catalytic activity in vitro, we here assessed the influ-
ence and functional in vitro and in vivo consequences of this
mutation on NatA complex formation and NatA activity in a
yeast model. By phenotypic screening in yeast, we show that
hNaa10 S37P displays a significantly impaired functionality in
vivo. Further, using immunoprecipitation, we show that the
human Naa10-Naa15 complex formation is negatively af-
fected by the S37P mutation, and that immunoprecipitated
hNatA S37P also displays a reduced in vitro catalytic activity
as compared with wild-type hNatA. Finally, quantitative Nt-
acetylome analyses suggest that reduced Nt-acetylation of
one or more target substrates contributes to the pathogenesis
of the Ogden syndrome.
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EXPERIMENTAL PROCEDURES
Plasmid Construction and Creation and Growth of Yeast Strains—
The following expression vectors were used to create the isogenic
yeast strains, pBEVY-URA, pBEVY-URA-hNAA15-hNAA10 (5) and
pBEVY-URA-hNAA15-hNAA10 S37P. The pBEVY-URA-hNAA15-
hNAA10 S37P expression vector was created from the pBEVY-URA-
hNAA15-hNAA10 by site directed mutagenesis according to the ma-
nufacturer’s instructions (QuikChange Site-Directed Mutagenesis Kit;
Stratagene, La Jolla, CA) using the following primers; hNAA10 T109C
forward: 5-CTTCTACCATGGCCTTCCCTGGCCCCAGCTC-3 and
hNAA10 T109C reverse: 5-GAGCTGGGGCCAGGGAAGGCCATGG-
TAGAAG-3. The correctness of all plasmids was verified by DNA
sequencing. S. cerevisiae strains were made as follows. The haploid
MATa strain BY4742 (Y10000, EUROSCARF) was transformed with
an empty expression vector pBEVY-URA and used as a control strain
termed yNatA. Y10976 (EUROSCARF) with NAA10::kanMX4 was
transformed with an empty expression vector pBEVY-URA and used
as a strain without yNatA termed yNatA. Y10976 was transformed
with an expression vector pBEVY-URA-hNAA15-hNAA10 and used
as a strain expressing hNatA, but not yNatA termed y[hNatA], and
finally Y10976 was transformed with an expression vector pBEVY-
URA-hNAA15-hNAA10 S37P, and used as a strain expressing human
NatA with a mutated hNaa10 S37P, but not expressing yeast NatA
termed y[hNatA S37P]. Yeast strains were selected and grown at
30 °C on plates lacking uracil. After pre-culturing in SC-medium lack-
ing uracil (SC-Ura) medium, strain phenotypes were determined on
YPD and YPD containing 0.3% caffeine or 0.2 g/ml cyclohemimide
(CHX).
Immunoprecipitation of hNatA—Yeast cultures (100 ml cultures)
were grown in SC-Ura at 30 °C and harvested in the exponential
growth phase (OD600 nm 3.0). Cells were pelleted, washed two times
in PBS (135 mM NaCl, 2.7 mM KCl, 7 mM Na2HPO4), and dissolved in
500 l yeast lysis buffer (50 mM Tris-HCl pH 7.6, 12 mM EDTA, 250 mM
NaCl, 140 mM Na2HPO4 supplemented with EDTA-free protease in-
hibitor (Roche Diagnostics)). To lyse yeast cells, 0.3 g of acid washed
425–600 m glass beads (Sigma) were added to each sample and
vortexed for 10 times 30 s (placing them on ice for 30 s in between).
The cell lysates were centrifuged at 7500  g for 10 min at 4 °C to
remove cell debris. 3 g of anti-hNaa15 was added to the supernatant
and incubated for 3 h on a rotating wheel at 4 °C. 100 l of Pierce
Protein AG Magnetic Beads (Thermo scientific) was added to the
mixture and this mixture was then incubated overnight on a rotating
wheel at 4 °C. The beads were isolated using a magnet, washed 3
times in yeast lysis buffer, 2 times in NAT buffer (50 mM Tris-HCl pH
7.4, 10% glycerol, 1 mM EDTA) and dissolved in 250 l NAT buffer.
For SDS-PAGE and Western blotting, SDS sample buffer was added
and samples boiled for 10 min at 95 °C. Anti-Naa15, anti-Naa10 and
anti--tubulin were used to visualize hNaa15, hNaa10 and -tubulin
(loading control) respectively. Protein bands imaged by a ChemiDoc
XRS system (BioRad) were quantified by densitometric scanning us-
ing the ImageLab 3.0 software from BioRad.
Nt-acetyltransferase Assay—Beads containing hNatA complexes
were mixed with 300 M acetyl-CoA, 300 M of the SESS-starting
substrate polypeptide NH2-SESSSKSRWGRPVGRRRRPVRVYP-
COOH and NAT-buffer and incubated for 30 min at 37 °C in a
shaker. The reaction was stopped by adding 6 l 10% TFA to the
mixture and acetylated peptides were quantified by RP-HPLC as
described previously (45). To calculate the NAT-activity per Naa10
molecule, the measured NAT activity of hNatA was set to 1, and the
NAT-activity of hNatA S37P was correlated with the relative amount
of hNaa10 present in each sample as determined by Western
blotting (supplemental Fig. S1). Western blots were imaged by a
ChemiDoc XRS from BioRad and the intensity of the hNaa10 bands
was determined by relative densitometry scanning using the Image-
Lab 3.0 software (BioRad). To account for the variance in the deter-
mination of hNaa10 present in each sample, standard deviations were
calculated by the equation
dX
x
 dAA 2 dBB 2, where A and dA
represent the measured product formation and standard deviation
from the in vitro acetyltransferase assay, and B and dB the relative
fold difference of the hNaa10 band intensities and the standard
deviation from these measurements respectively.
Preparation of Yeast Cell Extracts for N-terminal COFRADIC—The
yeast proteomes were prepared from 300 ml of culture at OD600 nm 
3.0 as described (1, 5). Cell lysis was essentially performed as de-
scribed above. Here, one EDTA-free protease inhibitor mixture tablet
was used per 100 ml of lysis buffer, and 1 ml of lysis buffer was used
for a pellet resulting from 300 ml of yeast culture. The cleared lysates
were subsequently analyzed by N-terminal COFRADIC analysis (1,
46). Briefly, solid guanidinium hydrochloride was added to a final
concentration of 4 M to denature all proteins. Subsequently, proteins
were reduced and alkylated simultaneously, using TCEP (1 mM final
concentration (f.c.)) and iodoacetamide (2 mM f.c.) respectively, for 1 h
at 30 °C in the dark. Subsequent steps of the N-terminal COFRADIC
setups analyzed were performed as described previously (47). The
proteome was digested overnight at 37 °C with sequencing-grade,
modified trypsin (Promega, Madison, WI) (enzyme/substrate of 1/100,
w/w).
LC-MS/MS Analysis and Data Processing—The obtained peptide
mixtures were introduced into an LC-MS/MS system, the Ultimate
3000 (Dionex, Amsterdam, The Netherlands) in-line connected to an
LTQ Orbitrap XL mass spectrometer (Thermo Fisher Scientific, Bre-
men, Germany). Samples were first loaded on a trapping column
(made in-house, 100 m internal diameter (I.D.) x 20 mm, 5 m beads
C18 Reprosil-HD, Dr. Maisch). After back-flushing from the trapping
column, the sample was loaded on a reverse-phase column (made
in-house, 75 m I.D.  150 mm, 5 m beads C18 Reprosil-HD, Dr.
Maisch). Peptides were loaded with solvent A (0.1% trifluoroacetic
acid, 2% acetonitrile), and were separated with a linear gradient from
2% solvent A’ (0.05% formic acid) to 55% solvent B’ (0.05% formic
acid and 80% acetonitrile) at a flow rate of 300 nL/min followed by a
wash reaching 100% solvent B’. The mass spectrometer was oper-
ated in data-dependent mode, automatically switching between MS
and MS/MS acquisition for the six most abundant peaks in a given
MS spectrum. Full scan MS spectra were acquired in the Orbitrap at
a target value of 1E6 with a resolution of 60,000. The six most intense
ions were then isolated for fragmentation in the linear ion trap, with a
dynamic exclusion of 60 s. Peptides were fragmented after filling the
ion trap at a target value of 1E4 ion counts. From the MS/MS data in
each LC run, Mascot Generic Files were created using the Mascot
Distiller software (version 2.3.01, Matrix Science). Although generat-
ing these peak lists, grouping of spectra was allowed with a maximum
intermediate retention time of 30 s and a maximum intermediate scan
count of five was used where possible. Grouping was done with 0.005
Da precursor tolerance. A peak list was only generated when the
MS/MS spectrum contained more than 10 peaks. There was no
de-isotoping and the relative signal to noise limit was set at two.
These peak lists were then searched with the Mascot search engine
(Matrix Science) using the Mascot Daemon interface (version 2.3,
Matrix Science).
Spectra were searched against the baker’s yeast (S. cerevisiae)
Swiss-Prot database (version 2011_04 of the UniProtKB/Swiss-Prot
protein database containing 7346 sequence entries (526,969 se-
quences in total)). 13C2D3-acetylation of lysine side-chains, carb-
amidomethylation of cysteine and methionine oxidation to methio-
nine-sulfoxide were set as fixed modifications for the N-terminal
COFRADIC analyses. Variable modifications were 13C2D3-acetyla-
tion and acetylation of protein N termini. Pyroglutamate formation
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of N-terminal glutamine was additionally set as a variable modifica-
tion. Mass tolerance on precursor ions was set to 10 ppm (with
Mascot’s C13 option set to 1) and on fragment ions to 0.5 Da.
Endoproteinase semi-Arg-C/P (Arg-C specificity with arginine-proline
cleavage allowed) was set as enzyme allowing no missed cleavages.
The peptide charge was set to 1, 2, 3 and instrument setting
was put to ESI-TRAP. Only peptides that were ranked one and scored
above the threshold score, set at 99% confidence, were withheld. The
estimated false discovery rate by searching decoy databases (a
shuffled version of the yeast Swiss-Prot database made by the
DBToolkit algorithm (48)) was found to lie between 0.89% and
1.17% on the spectrum level. Quantification of the degree of Nt-
Acetylation was performed as described previously (1). All data
management was done in ms_lims (49). The mass spectrometry
proteomics data have been deposited to the ProteomeXchange
Consortium (http://proteomecentral.proteomexchange.org) via the
PRIDE partner repository (50) with the data set identifier PXD000316
and DOI 10.6019/PXD000316 and PRIDE accessions 29985–29988.
RESULTS
Human NatA S37P Only Partially Rescues Yeast NatA-
Phenotypes—We previously showed that heterologous com-
binations of human and yeast NatA subunits neither produced
active NatA nor complemented yNatA- phenotypes (5).
Therefore and to determine if ectopically expressed hNatA
S37P is capable of suppressing the yeast NatA- pheno-
types, hNAA15 was expressed with hNAA10 or hNAA10 S37P
in yeast, to respectively generate a yeast strain expressing
hNatA (y[hNatA]) or mutant human NatA (y[hNatA S37P]) (Figs.
1A and 1B). We found that, in contrast to hNatA expression,
phenotype profiling of hNatA S37P expression showed a re-
duced suppression of the observed NatA- phenotypes (Fig.
1C). More specifically, sensitivity of the NatA- yeast to caf-
feine and cycloheximide (CHX) was nearly completely sup-
pressed by hNatA expression, whereas hNatA S37P expres-
sion resulted in a reduced complementation, suggesting a
diminished functionality of hNatA S37P in vivo.
hNatA S37P Displays a Reduced hNaa10-hNaa15 Complex
Formation, and a Reduced Catalytic Activity In Vitro—Yeast
studies revealed that the catalytic subunit Naa10 associates
with the ribosome through its interaction with the auxiliary
subunit Naa15 where it is brought in close proximity to its
nascent polypeptide substrates (51). Furthermore, the recent
structure published by Liszczak et al. demonstrated that
Naa10 binds in a tight binding pocket of Naa15 and that
complex formation alters the catalytic site and activates
Naa10’s catalytic activity (27). To investigate whether the lack
of full NatA- phenotype complementation by hNaa10 S37P
and hNaa15 was due to a lack of proper complex formation
and/or NatA catalytic capacity, we performed immunoprecipi-
tation of the hNatA complex from the yeast strains expressing
the mutant or wild-type complex using anti-hNaa15 antibodies.
FIG. 2. Immunoprecipitated hNatA S37P shows a reduced com-
plex formation and reduced NAT activity. Yeast strains were grown,
harvested, lysed and subjected to hNatA immunoprecipitation using
anti-hNaa15 antibodies and activity measurements. A, Immunopre-
cipitation of the hNatA complex with antibodies against the auxiliary
subunit hNaa15. Immunoprecipitates and cell lysates were analyzed
by SDS-PAGE and Western blotting. -actin or an unspecific band
(indicated with an asterisk) served as loading controls for the cell
lysates and immunoprecipitates respectively. B, NAT-activity (per
Naa10-molecule) of hNaa10 WT and S37P in complex with hNaa15.
hNatA complexes were immunoprecipitated with anti-hNaa15 and
used for in vitro NAT-activity measurements. The amount of Naa10
present in each sample was detected by Western blotting and den-
sitometric scanning (Figure S1). NAT-activity measurements were
performed in triplicates. Error bars include the standard deviation
from both NAT-activity measurements and the densitometric scan-
ning of Naa10 bands. Statistically significant results are indicated with
an asterisk (p  0.05). The p value was calculated using Student’s t
test.
FIG. 1. Human hNatA S37P expression in yeast only partially
suppresses the yeast NatA- Phenotypes. A, yNAA10-specific
PCR confirming the ynaa10::kanMX deletion cassette in the yNatA-,
y[hNatA] and y[hNatA-S37P] strains. B, The yeast strains were ana-
lyzed by SDS-PAGE and Western blotting using anti-hNaa10 and
anti-hNaa15 antibodies, confirming equal expression of the human
NatA subunits in the y[hNatA] and y[hNatA S37P] strains (an unspe-
cific band served as loading control (indicated by an asterisk)). C,
Strains were grown in synthetic medium (-URA) overnight until the
exponential phase of growth and equal cell numbers were inoculated
in a YPD-pre-culture before plating of equal amounts of cells for
growth in a 10-fold dilution series on YPD, YPD  0.3% caffeine, or
YPD  0.2 g/ml cycloheximide (CHX) for 3 days at 30 °C (yNatA,
yNatA- (2 clones), y[hNatA] (2 clones) and y[hNatA S37P] (2 clones)).
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Immunoprecipitation experiments clearly show that hNaa10 and
hNaa15 are capable of forming a complex when overexpressed
in yeast (Fig. 2A). However, the mutant hNaa10 S37P is more
than twofold less capable of forming this functional hNatA
complex as determined by anti-hNaa15 immunoprecipitation
followed by Western blotting detecting co-immunoprecipi-
tated hNaa10 (Fig. 2A and supplemental Fig. S1). Further-
more, we assayed the Nat-activity of the immunoprecipitated
hNatA complexes (per Naa10 molecule) by an in vitro acetyl-
transferase assay. A significant decrease in product formation
was measured for hNatA S37P (Fig. 2B) suggesting that in
addition to hNaa10 S37P being less capable of forming a com-
plex with hNaa15, the hNatA S37P complex also has a reduced
catalytic activity in comparison to the hNatA complex.
Quantitative Nt-acetylome Analyses Reveal a Reduced De-
gree of Nt-acetylation for the Majority of NatA Substrates in the
hNatA S37P Yeast Strain—Because phenotypic characteriza-
tion in yeast disclosed a significantly impaired functionality of
hNatA S37P in addition to a reduced complex formation and
enzymatic activity when assaying the immunoprecipitated
hNatA S37P, the in vivo outcome on the steady-state levels of
protein Nt-acetylation was studied. Using N-terminal
COFRADIC, the in vivo Nt-acetylomes of the y[hNatA] and y[h-
NatA S37P] yeast proteomes were quantitatively analyzed
next to the yNatA and yNatA- Nt-acetylomes. In addition to
the study of species-specific NatA substrate repertoires at the
proteome-wide level, this study points to potential differences
in the in vivo substrate specificity profiles of the wild-type
yNatA, hNatA and mutant hNatA complex. Here, in vitro
13C2D3-acetylation is used to discriminate between in vivo
Nt-acetylated and free N termini as this introduces a 5 Da
mass spacing between the free and Nt-acetylated form of an
TABLE I
Overview of N-terminal acetylation in the yeast N-terminomes of yNatA, yNatA-, yhNatA	 and yhNatA S37P	. Only Swiss-Prot database
annotated N-termini (start  1 or 2) of which the degree of Nt-Acetylation could be univocally calculated/determined in the respective
setups analyzed and were compliant with the rules of N-terminal acetylation and iMet processing (54) were used for the overall calculation
of Nt-Acetylation
yNatA yNatA- yhNatA	 yhNatA S37P	
Full
(%)
Full 
partial (%) Total
Full
(%)
Full 
partial (%) Total
Full
(%)
Full 
partial (%) Total
Full
(%)
Full 
partial (%) Total
NatA
A- 20.9 64.2 67 0.0 0.0 63 1.5 69.2 65 0.0 69.2 65
C- 0.0 0.0 1 0.0 0.0 2 0.0 0.0 4 0.0 0.0 2
G- 0.0 14.3 28 0.0 0.0 29 0.0 27.6 29 0.0 16.7 30
S- 84.0 99.6 238 0.0 5.2 211 8.8 97.8 227 0.8 96.6 236
T- 13.7 68.6 51 0.0 0.0 52 0.0 60.0 45 0.0 60.4 48
V- 0.0 13.0 46 0.0 4.7 43 0.0 18.6 43 0.0 15.2 46
Total 51.2 75.2 431 0.0 3.2 400 5.1 74.9 413 0.5 73.4 427
NatD
S- (H2A) 100.0 0.0 1 100.0 0.0 1 100.0 0.0 1 100.0 0.0 1
Total 100.0 0.0 1 100.0 0.0 1 100.0 0.0 1 100.0 0.0 1
NatB
MD- 98.3 100.0 59 98.1 100.0 52 98.6 100.0 72 98.4 100.0 61
ME- 97.1 100.0 35 96.7 100.0 30 97.1 100.0 34 91.4 100.0 35
MN- 82.0 100.0 50 75.6 100.0 45 75.5 100.0 53 74.0 100.0 50
MQ- 38.5 84.6 13 18.8 81.3 16 25.0 85.0 20 33.3 86.7 15
Total 87.9 98.7 157 81.8 97.9 143 83.2 98.3 179 83.2 98.8 161
NatC
MF- 54.5 72.7 11 42.9 42.9 7 45.5 72.7 11 40.0 60.0 10
MI- 5.3 52.6 19 5.6 38.9 18 10.0 50.0 20 5.0 45.0 20
ML- 29.0 38.7 31 25.0 30.0 20 32.4 48.6 37 26.7 36.7 30
MY- 20.0 50.0 10 28.6 57.1 7 20.0 60.0 10 10.0 70.0 10
Total 25.4 49.3 71 21.2 38.5 52 26.9 53.8 78 20.0 47.1 70
None
P- 0.0 0.0 31 0.0 0.0 31 0.0 0.0 29 0.0 0.0 26
MP- 0.0 0.0 2 0.0 0.0 1 0.0 0.0 3 0.0 0.0 1
Total 0.0 0.0 33 0.0 0.0 32 0.0 0.0 32 0.0 0.0 27
Other
MA- 0.0 25.0 4 0.0 0.0 2 0.0 66.7 3 0.0 33.3 3
MG- 0.0 25.0 4 0.0 33.3 3 0.0 50.0 2 0.0 66.7 3
MH- 0.0 0.0 1 0.0 0.0 1
MK- 2.6 20.5 39 0.0 18.2 33 2.6 26.3 38 2.8 33.3 36
MM- 0.0 100.0 5 0.0 80.0 5 0.0 80.0 5 0.0 100.0 4
MS- 0.0 81.8 11 0.0 80.0 5 0.0 88.9 9 0.0 75.0 4
MT- 0.0 40.0 10 0.0 28.6 7 0.0 55.6 9 0.0 57.1 7
MV- 0.0 50.0 10 0.0 40.0 5 0.0 37.5 8 0.0 33.3 6
Total 1.2 39.8 83 0.0 31.1 61 1.3 44.0 75 1.6 44.4 63
Grand total 48.8 70.6 776 18.7 27.9 689 24.8 72.1 778 20.3 71.3 749
Nt-acetylome Analysis of the Ogden NAA10 S37P Mutant
Molecular & Cellular Proteomics 13.8 2035
N-terminal peptide, enabling the calculation of the extent of
Nt-acetylation (5, 52). Overall, in the four yeast strains ana-
lyzed, 1608 unique yeast N termini originating from 1277 yeast
proteins were identified (supplemental Table S1). Here, an N
terminus is defined as a peptide that is either in vivo Nt-
acetylated or in vitro 13C2D3-acetylated (i.e. an in vivo free N
terminus) and starts at position 1 or 2 of the Swiss-Prot
annotated protein sequence, or an in vivo Nt-acetylated pep-
tide with a starting position beyond 2. Of the 1,608 N termini,
1212 N termini were in compliance with the rules of Nt-
acetylation (53) and initiator methionine (iMet) processing
(supplemental Table S1). Of these, 1056 started at position 1
or 2 (1011 proteins), whereas 156 started beyond position 2
(145 proteins), the latter indicative of alternative translation
initiation (54). 396 N termini did not comply with the rules of
Nt-acetylation and iMet processing and thus indicate post-
translational Nt-acetylation (54) or non-AUG translation initia-
tion (55) among others. Interestingly, the majority of NatA type
substrate N termini falling in this category were shown to be
modified in a NatA dependent fashion (see below). 607 unique
N termini were identified in all four setups analyzed (38% of all
unique protein N termini identified) (supplemental Table S1).
The difference in the degree of Nt-acetylation could be cal-
culated for 97% to 99% of the N termini identified in the
different yeast N-terminomes (supplemental Table S1). Con-
siderable variations in the degree of Nt-acetylation, defined as
a minimum difference of 10% (1), of yeast N termini with a
database annotated start position were almost exclusively
confined to the NatA type class of N termini. For the overall
majority of these, Nt-acetylation falls to undetectable levels in
the yNatA- setup (i.e. the fraction of (partially) Nt-acetylated
NatA type N termini drops from 75% to about 3%, (Table I and
supplemental Table S1)), indicative for the fact that for most of
these, no NatA-like redundant activity can be observed. In
total, 576 database annotated NatA type N termini were iden-
tified (or 55% of all database annotated N termini identified).
For 402 (or 70%) of these, the NatA dependence of Nt-
acetylation could be determined pointing to 332 genuine NatA
substrate N termini in yeast (i.e. 83% of all determined NatA
type N termini represent yNatA and/or hNatA (S37P) sub-
strate(s) and thus indicative for the fact that the vast majority
of the nondetermined NatA type N termini also represent NatA
substrate N termini (supplemental Table S1)). Further, and in
compliance with the (X)PX rule of Nt-acetylation stating the
prevention of Nt-acetylation under all circumstances (53), all
determined NatA type X-Pro-starting N termini were found to
be N-terminal free under all conditions analyzed (Table I and
supplemental Table S1). Here, NatA substrate N termini were
considered when corresponding N-terminal peptides were
found to be completely nonacetylated in the yNatA- strain as
compared with the yNatA, y[hNatA] and/or y[hNatA S37P]
strains, or displayed a shift in Nt-acetylation larger than 10%
as compared with the control or hNatA versus hNatA S37P
sample (supplemental Table S1). When correlating the de-
grees of Nt-acetylation of the NatA type N termini identified in
the hNatA versus the hNatA S37P N-terminome data sets
(Fig. 3), a general decrease in the degree of Nt-acetylation can
be observed, indicative for the fact that the mutation re-
duces the efficiency of hNatA-dependent Nt-acetylation
(Figs. 3 and 4), an observation matching the phenotypic
analyses and reduced enzymatic activity of the complex in
vitro (Figs. 1 and 2).
Species-specific NatA Nt-acetylation Substrate Specificity
Profiles Indicate a Co-evolution of NatA Complexes With Their
Species-matching Substrate Pools—Related to the various
orthologs/mutant NatA complexes (i.e. yNatA, hNatA versus
hNatA S37P) studied alongside their substrate specificity pro-
files, and in analogy with what was reported previously (5), all
yNatA substrate N termini displaying a degree of Nt-acetyla-
tion 20%, were also found to be Nt-acetylated in the yeast
strain ectopically expressing hNatA. In general, 60% of the
yNatA substrates displayed a higher degree of Nt-acetylation
when compared with the Nt-acetylation levels of hNatA sub-
strate N termini, whereas only 12% of the hNatA substrate N
termini displayed an increased level of Nt-acetylation as com-
pared with the Nt-acetylation levels observed for yNatA (sup-
plemental Table S1, Figs. 4 and 5A). This indicates that de-
spite the fact that the majority of substrates were found to be
Nt-acetylated in both systems, differences in the efficiency of
Nt-acetylation can be observed and that, under the conditions
analyzed, in general yNatA seems to be the more efficient
FIG. 3. hNatA S37P expression in yeast significantly reduces the
efficiency of NatA-mediated N-terminal acetylation at the pro-
teome-wide level. Scatterplot displaying the correlation of the de-
grees of Nt-acetylation of the NatA type class N termini (i.e. Ser-, Ala-,
Thr-, Val-, and Gly- starting N termini). Correlation of the degrees of
Nt-acetylation of the determined NatA type class N termini identified
in the yeast N-terminomes of a human NatA (hNatA) expressing strain
(X-axis) and a S37P mutant human NatA (hNatA S37P) expressing
strain (Y-axis) (n 347). Only in 6.3% of the cases, the S37P mutation
causes an increased degree of Nt-Ac as compared with the wild type
hNatA whereas in 24.5% about equal levels of Nt-Ac (less than 10%
difference in the degree of Nt-Ac) could be observed and thus for the
majority of NatA-substrates (69.2% of NatA type N termini), the S37P
mutation causes a decrease in the levels of Nt-Ac.
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NatA complex in yeast as compared with hNatA, an observa-
tion in line with the phenotypic profiling of these strains. When
taking two sets of NatA substrate N termini displaying the
largest variation in Nt-acetylation observed in the systems
analyzed (i.e. 30 N termini displaying the largest increase in
Nt-acetylation in the hNatA system and 30 in the yNatA sys-
tem), it is noteworthy that an increased Nt-acetylation poten-
tial of hNatA toward Ala-starting N termini is observed,
whereas yNatA is more efficient in acetylating Ser-starting N
termini (Fig. 5B). This observation is in line with our previously
reported distribution analyses of Nat type substrates in the
proteomes of yeast and human, that demonstrated that
(Met-)Ala- N termini occur 3-fold more (up to 23%) in humans,
whereas (Met-)Ser- N termini occurrence decreased from
23% to 11% when comparing yeast versus human pro-
teomes (Fig. 5C) and (1). Overall, this hints to the fact that
NatA substrate specificity/efficiency of Nt-acetylation has
co-evolved with the repertoire of NatA type substrates ex-
pressed (Fig. 5).
DISCUSSION
By introducing the human wild-type or mutant NatA S37P
complex into yeast lacking NatA (NatA-), we created a model
system enabling the study of the Ogden syndrome mutant
NatA, thereby revealing the functional impairment of hNatA
S37P in vivo. Overall, the wild-type human NatA complex
phenotypically complemented the NatA- strain, whereas
only a partial rescue was observed for the mutant NatA com-
plex (Fig. 1C). Biochemical characterization of the mutant
hNaa10 S37P previously showed a reduced NAT-activity as
compared with hNaa10 WT (40). In this study, immunopre-
cipitation experiments revealed a significantly reduced
hNaa10 S37P/hNaa15 complexation (as deduced from the
difference in Naa10 present in anti-Naa15 immunoprecipi-
tates), next to a reduced catalytic activity for the hNatA S37P
complex in comparison with the wild type hNatA complex
(Fig. 2). Overall this led us to postulate that multiple mecha-
nisms (i.e. reduced complex formation and catalytic activity)
might be at play lowering the ribosomal NatA-activity in the
y[hNatA S37P] as compared with the y[hNatA] yeast strain.
This postulation was strengthened by the quantitative Nt-
acetylome analyses performed, revealing a reduced degree of
Nt-acetylation for the majority of NatA substrates in the
y[hNatA S37P] yeast strain (Fig. 3).
Noteworthy, and besides the hundreds of NatA substrate N
termini identified, 12 database annotated NatA type substrate
FIG. 4. Nt-acetylome analyses reveal a reduced degree of Nt-acetylation for the majority of NatA substrates in the hNatA S37P as
compared with the hNatA yeast setup. MS-spectra from the AG- (A) and SQ- (B) starting N-terminal peptides (doubly charged precursors)
of the Pre-rRNA-processing protein ESF1 (2AGENPKKEGVDAR14) and the TPR repeat-containing protein associated with Hsp90
(2SQFEKQKEQGNSLFKQGLYR21) demonstrate these to be genuine yNatA substrate N termini as these were found to be partially (6%) or fully
Nt-acetylated and 0% Nt-acetylated in the control and yNatA- yeast proteomes, respectively. Two distinguishable isotopic envelopes could
clearly be distinguished in the y[hNatA] and y[hNatA S37P] yeast strains [i.e. the in vivo acetylated (Ac) and in vitro 13C2 and trideutero-
acetylated forms (13C2D3)] (right four panels) indicative for the fact that these N termini are only partially in vivo Nt-acetylated. The AG- and
SQ- starting N-terminal peptides were found to be 65 and 50%, and 32 and 23% Nt-acetylated in the hNatA and hNatA S37P setups
respectively, thus showing a reduced degree of Nt-acetylation of respectively 15 and 9%.
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N termini were still found to be (partially) Nt-acetylated in the
yNatA- proteome sample analyzed (supplemental Table S1).
When looking into their sequence profile it is of note that they
predominantly display the NatD type substrate specificity (6).
Of note, the SGGKG- starting N terminus of H2A was fully
Nt-acetylated in all four setups analyzed in agreement with it
being a NatD substrate (56). In contrast, four other SG-start-
ing N termini were found to be partially Nt-acetylated in the
yNatA- setup with a reduced degree of Nt-acetylation as
compared with the other setups, indicative for the fact that
besides being Nt-acetylated by NatA, another Nat activity
(presumably and most likely NatD) is responsible for these
NatA redundant Nt-acetylation activities. Thus, some new
NatD substrates might have been identified.
Further, next to the canonical NatA type substrate N termini
identified, some N termini displaying an unknown Nat type
substrate specificity (i.e. Met-starting N termini normally pro-
cessed by MetAPs because their second amino acid has a
small gyration radius (57–60)) also displayed a significant
change in their degree of Nt-acetylation in one or more of the
setups analyzed (supplemental Table S1). More specifically it
seems that Met-Ser- and Met-Thr-starting N termini, whereas
FIG. 5. Species-specific NatA substrate specificity profiles indicate a co-evolution of NatA complexes with their species-matching
substrate pools. A, Scatterplot displaying the correlation of the degrees of Nt-acetylation of the NatA type class N termini (i.e. Ser-, Ala-, Thr-,
Val-, and Gly- starting N termini). Correlation of the degrees of Nt-acetylation of the determined NatA type class N termini identified in the yeast
N-terminomes of a yeast NatA (yNatA) (x-axis) and a human NatA (hNatA) expressing yeast strain (y-axis) (n  333). In 11.7% of the cases,
hNatA expression results in an increase of Nt-Ac as compared with the yNatA whereas in 27.6% of the cases about equal levels of Nt-Ac (less
than 10% difference in the degree of Nt-Ac) could be observed. For 60.7% of identified NatA-substrates, hNatA expression resulted in a lower
level of Nt-Ac as compared with the levels in control yeast (yNatA). B, A differential iceLogo (63) representation was created using two y/hNatA
substrate subsets for which the hNatA (n  30) or yNatA (n  30) Nt-acetylation efficiency differed most notably (as deduced from the
proteomics data and based on the degrees of Nt-acetylation calculated), thus representing the enriched and depleted residues in these
respective NatA substrate sets. Statistically significant residues (p  0.05) are plotted with the size of the amino acid proportional to the
difference observed in Nt-acetylation efficiency between human and yeast NatA. Multiple sequence alignments are given as 1 to 6
corresponding to the first 6 N-terminal residues of NatA substrates and with Nt-acetylation occurring at position 1. C, Stacked horizontal bar
charts of the differential alanine and serine occurrence at position 2 of yeast (S. cerevisiae), fruit fly (D. melanogaster), and human (H. sapiens)
iMet starting Swiss-Prot database protein entries (respectively 6620, 3168 and 20114 reviewed entries in the UniProtKB/Swiss-Prot protein
database release 2013_07).
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having a yNatA redundant yNAT capable of Nt-acetylating
these (i.e. these were partially Nt-acetylated in the yNatA-
setup), hNatA and/or hNatA S37P expression increased their
degree of Nt-acetylation. In fact, often these N termini showed
an increased degree of Nt-acetylation in the hNatA setup(s) as
compared with the yNatA setup. This could suggest that
hNatA has evolved to more efficiently Nt-acetylate these
types of N termini. In this respect, it is noteworthy that recom-
binant Naa10 and immunoprecipitated hNatA (from human
HeLa cells) were found to inefficiently Nt-acetylate Met-start-
ing oligopeptides (10). However another plausible though not
mutually exclusive explanation might be a perturbed NatE
activity, the second catalytic subunit enclosed in the NatA
complex. First, human Naa50 was found to Nt-acetylate Met-
Leu- starting N termini in vitro, a substrate specificity distinct
from that of the NatA complex, and therefore considered a
separate NAT type, NatE (9). Second, a proteome derived
peptide library Nt-acetylation screen making use of recombi-
nant hNaa50 confirmed and diversified this initial substrate
specificity profile to hold Met-Lys, Met-Met and Met-Ala next
to Met-Leu- oligopeptide hNaa50 substrates (10). Moreover,
because siNatA knockdown studies in human HeLa cells pre-
viously demonstrated a reduced level of hNaa50 and the fact
that in addition to the reduced degree of Nt-acetylation of
proteins matching the NatA substrate specificity; siNatA
knockdown showed the reduced acetylation of the MLGP-
starting hnRNP F N terminus (5). Thus, it is not unlikely that in
vivo Naa50 substrates might include Met-Ser- and Met-Thr-
starting N termini and that the presence or absence of Naa10
and Naa15 affects Naa50 substrate acetylation. Interestingly,
in Ogden syndrome cells, this implies that next to a decrease
in NatA activity, hNaa10 S37P might indirectly affect NatE
activity and potentially a reduction in Nt-acetylation of NatE
substrates.
Further, besides the database annotated N termini identi-
fied, these datasets also holds numerous N termini not com-
pliant with the current rules for N-terminal modifications; ei-
ther no iMet is present and/or the NAT rules of Nt-acetylation
do not match the canonical Nt-acetylation patterns (54). Var-
ious of these N termini belonging to the NatA type class of N
termini and display a NatA dependence of Nt-acetylation,
hinting to the fact that these N termini could represent either
post-translational Nt-acetylation events (54), co-translational
acting (di-)aminopeptidase activity, non-cognate (non-AUG)
co-translational translation initiation events (55) or simply
wrong database annotations. In this context it is interesting to
note that, on proteolytic loss of their transit/signal sequence,
the mature N termini of various mitochondrial localized pro-
teins (such as the N termini of the mitochondrial ATPase-
stabilizing factor 9 kDa (loss of 1–23 transit sequence) and the
acyl carrier protein (loss of 1–36 transit sequence)) were here
found to be (partially) Nt-acetylated in a NatA dependent
manner (i.e. found to be 62 and 7% Nt-acetylated in the
control setup, while being free in the yNatA- setup)
(supplemental Table S1) and thus indicative of the fact that
NatA or Naa10 might act post-translationally in mitochondria
on import, reminiscent of the post-translational NatA-like ac-
tivities observed in plant plastids (11) and other eukaryotes
with complex plastids (61), or alternatively act post-transla-
tionally in the cytosol on mitochondrial export. Because none
of the eight proteins encoded by the mitochondrial genome
were identified (62), their N-terminal modification status could
not be assessed to ascertain the existence of mitochondrial
Nat activity.
In conclusion, our yeast model supports a reduced NatA
complex formation and catalytic capacity, and thereby a re-
duction of Nt-acetylation of NatA substrates as a cause for the
Ogden syndrome.
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